Related references
Note: Only part of the references are listed.Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland
Gary L. O'Brien et al.
CLINICAL BREAST CANCER (2019)
A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer
S. Dent et al.
CURRENT ONCOLOGY (2019)
Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden
Elham Hedayati et al.
PLOS ONE (2019)
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer Final Analysis of the HannaH Phase 3 Randomized Clinical Trial
Christian Jackisch et al.
JAMA ONCOLOGY (2019)
Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
Marco Mazzotta et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Use of subcutaneous and intravenous trastuzumab: Real-world experience from three hospitals in Sweden
A. Valachis et al.
CANCER RESEARCH (2019)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
The evolution of biosimilars in oncology, with a focus on trastuzumab
N. A. Nixon et al.
CURRENT ONCOLOGY (2018)
A multi-center evaluation of clinical pathways cost and time using real-life data in 411 breast cancer patients treated with intravenous versus subcutaneous Trastuzumab
C. Bernard Marty et al.
EUROPEAN JOURNAL OF CANCER (2018)
An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting
I. Cicin et al.
EUROPEAN JOURNAL OF CANCER (2018)
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study
Kyung Hae Jung et al.
ONCOLOGIST (2018)
COST-MINIMIZATION ANALYSIS OF TRASTUZUMAB INTRAVENOUS VERSUS TRASTUZUMAB SUBCUTANEOUS REGIMEN FOR BREAST CANCER MANAGEMENT IN HONG KONG
V. W. Lee et al.
VALUE IN HEALTH (2018)
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study
X. Pivot et al.
EUROPEAN JOURNAL OF CANCER (2017)
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study
X. Pivot et al.
EUROPEAN JOURNAL OF CANCER (2017)
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
J. Gligorov et al.
EUROPEAN JOURNAL OF CANCER (2017)
SUBCUTANEOUS VS INTRAVENOUS ADMINISTRATION OF TRASTUZUMAB IN HER2+BREAST CANCER PATIENTS: A MONTENEGRIN COST-MINIMIZATION ANALYSIS
V Todorovic et al.
VALUE IN HEALTH (2017)
Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients
Alberto Farolfi et al.
ONCOTARGET (2017)
Cost minimization analysis of Herceptin subcutaneous versus Herceptin intravenous treatment for patients with HER2+ Breast cancer in Greece
C. Mylonas et al.
JOURNAL OF CANCER POLICY (2017)
Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
G. Lopez-Vivanco et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous manual syringe injection or intravenously in women with HER2-positive early breast cancer
Angelica L. Quartino et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up
Christian Jackisch et al.
EUROPEAN JOURNAL OF CANCER (2016)
A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer
Erwin De Cock et al.
CANCER MEDICINE (2016)
Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach
Clemente Ponzetti et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2016)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
E. Senkus et al.
ANNALS OF ONCOLOGY (2015)
Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers
C. Jackisch et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2015)
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study
C. Jackisch et al.
ANNALS OF ONCOLOGY (2015)
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
X. Pivot et al.
ANNALS OF ONCOLOGY (2014)
Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer
Mark Sanford
TARGETED ONCOLOGY (2014)
Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males
Chris J. Wynne et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Xavier Pivot et al.
LANCET ONCOLOGY (2013)
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
Gustavo Ismael et al.
LANCET ONCOLOGY (2012)
Share Paper
